Cited 3 times in
Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김윤정 | - |
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 이경아 | - |
dc.date.accessioned | 2023-03-22T02:00:59Z | - |
dc.date.available | 2023-03-22T02:00:59Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 2234-3806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193499 | - |
dc.description.abstract | Background: BRCA testing is necessary for establishing a management strategy for ovarian cancer. Several BRCA testing strategies, including germline and somatic testing, are implemented in clinical practice in Korea. We aimed to comparatively evaluate their cost-effectiveness from patients' perspective. Methods: We developed a decision model comprising five BRCA testing strategies implemented in Korea: (1) germline testing first, followed by somatic tumor testing for patients without a germline variant; (2) somatic testing first, followed by germline testing for patients with a variant detected by somatic testing; (3) both germline and somatic testing; (4) germline testing alone; and (5) somatic testing alone, with no testing as the comparator. One-way sensitivity analysis was conducted to test the uncertainty of key parameters. Results: Assuming a willingness-to-pay of $20,000 per progression-free life-year gain (PF-LYG), all five strategies were considered cost-effective. Strategy 4 was the most cost-effective option, with an incremental cost-effectiveness ratio (ICER) of $2,547.7 per PF-LYG, followed by strategy 1, with an ICER of $3,978.4 per PF-LYG. Even when the parameter values were varied within the possible range, the ICERs of all strategies did not exceed the willingness-to-pay threshold. Conclusions: Considering the importance of knowing a patient's BRCA gene status, germline testing first, followed by somatic testing, may be a reasonable option. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Society for Laboratory Medicine | - |
dc.relation.isPartOf | ANNALS OF LABORATORY MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Cost-Benefit Analysis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Germ Cells / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Ovarian Neoplasms* / diagnosis | - |
dc.subject.MESH | Ovarian Neoplasms* / genetics | - |
dc.subject.MESH | Ovarian Neoplasms* / pathology | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients With Advanced Ovarian Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Laboratory Medicine (진단검사의학교실) | - |
dc.contributor.googleauthor | Jaehyeok Jang | - |
dc.contributor.googleauthor | Yoonjung Kim | - |
dc.contributor.googleauthor | Jae-Hoon Kim | - |
dc.contributor.googleauthor | Sun-Mi Cho | - |
dc.contributor.googleauthor | Kyung-A Lee | - |
dc.identifier.doi | 10.3343/alm.2023.43.1.73 | - |
dc.contributor.localId | A00793 | - |
dc.contributor.localId | A00876 | - |
dc.contributor.localId | A02647 | - |
dc.relation.journalcode | J00164 | - |
dc.identifier.eissn | 2234-3814 | - |
dc.identifier.pmid | 36045059 | - |
dc.subject.keyword | Advanced ovarian cancer | - |
dc.subject.keyword | BRCA testing | - |
dc.subject.keyword | Cost-effectiveness analysis | - |
dc.contributor.alternativeName | Kim, Yoon Jung | - |
dc.contributor.affiliatedAuthor | 김윤정 | - |
dc.contributor.affiliatedAuthor | 김재훈 | - |
dc.contributor.affiliatedAuthor | 이경아 | - |
dc.citation.volume | 43 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 73 | - |
dc.citation.endPage | 81 | - |
dc.identifier.bibliographicCitation | ANNALS OF LABORATORY MEDICINE, Vol.43(1) : 73-81, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.